House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Rheumatology

Spondyloarthritis in over 16s: diagnosis and management

NICE · 2017 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE spondyloarthritis guidance covers recognition and referral, specialist imaging, axial and peripheral treatment, function and long-term risks. Normal inflammatory markers, negative HLA-B27 or normal radiographs do not individually exclude disease. Biological and targeted therapy decisions remain tied to their specific eligibility and response criteria.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Do not exclude disease on a single negative finding

  • Consider musculoskeletal and extra-articular clues, including inflammatory back pain, enthesitis, dactylitis, psoriasis and uveitis. Genitourinary infection and a family history can increase suspicion; disease can coexist with inflammatory bowel disease. [1]
  • Do not rule out spondyloarthritis because HLA-B27 is negative or inflammatory markers are normal. Axial disease may also be present without sacroiliitis on plain radiographs. [1]
  • Seek same-day ophthalmology assessment for symptoms of acute anterior uveitis, such as eye pain, redness, light sensitivity or blurred vision. This remains important during arthritis flares. [1]

Apply the axial and peripheral referral pathways

  • For back pain beginning before 45 and lasting over 3 months, refer to rheumatology when at least 4 listed criteria are present: onset before 35, waking in the latter half of the night, buttock pain, improvement with movement or within 48 hours of NSAIDs, affected first-degree relative, arthritis, enthesitis or psoriasis. [1]
  • For low back pain starting before age 45 and lasting over 3 months, test HLA-B27 when exactly 3 referral criteria are present and refer if positive. Criteria are onset before 35, second-half-of-night waking, buttock pain, improvement with movement or within 48 hours of NSAIDs, a first-degree relative with spondyloarthritis, or current/past arthritis, enthesitis or psoriasis. If criteria are unmet but suspicion remains, seek repeat assessment when new features develop. [1]
  • Urgently refer suspected new inflammatory arthritis for the appropriate rheumatology assessment, recognising the distinct pathways for rheumatoid arthritis, gout and acute crystal arthritis. Refer dactylitis for spondyloarthritis assessment. [1]
  • Refer enthesitis without an apparent mechanical cause if persistent or multisite, or accompanied by nonmechanical back pain, current/past uveitis or psoriasis, gastrointestinal or genitourinary infection, inflammatory bowel disease, or a first-degree relative with spondyloarthritis or psoriasis. [1]

Use sequential imaging without treating a negative scan as definitive

  • For suspected axial disease, offer sacroiliac radiographs unless the skeleton is likely immature. If radiographs do not establish the specified sacroiliitis criteria, or are inappropriate because of immaturity, request unenhanced MRI using an inflammatory back-pain protocol. [1]
  • Use the specified MRI criteria, but do not exclude axial disease solely because they are not met. Consider specialist radiology review when imaging and clinical suspicion differ, and follow-up MRI if suspicion remains high. [1]
  • For symptomatic peripheral disease in hands or feet, start with radiographs and consider ultrasound if diagnosis remains uncertain. Once peripheral disease is confirmed, assess the sacroiliac joints radiographically for axial involvement even without symptoms. [1]

Match medication to axial or peripheral disease

  • For axial pain, offer an NSAID at the lowest effective dose with clinical assessment, risk monitoring and consideration of gastroprotection. If the maximum tolerated dose is inadequate after 2–4 weeks, consider another NSAID. [1]
  • For nonprogressive peripheral monoarthritis, consider local corticosteroid injection alone. Offer a conventional DMARD for peripheral polyarthritis, oligoarthritis or persistent or progressive monoarthritis. [1]
  • Choose the conventional DMARD with attention to preferences, pregnancy plans, alcohol intake, extra-articular disease, comorbidity and adverse effects. If the maximum tolerated dose is inadequate for at least 3 months, consider switching or adding another conventional DMARD. [1]
  • For peripheral symptoms, NSAIDs may supplement DMARDs at the lowest effective dose for the shortest duration. If inadequate, consider local or intramuscular corticosteroids or a short oral course as an adjunct. [1]
  • Continue a biological or targeted synthetic DMARD only when there is clear treatment response, applying the drug-specific appraisal’s definition and review interval. When several medicines are clinically suitable, discuss their benefits and disadvantages and use the least expensive, accounting for administration costs, dosage, price per dose and commercial arrangements. [1]
  • After treating the initial infection, do not prescribe antibiotics for 4 weeks or longer solely to manage reactive arthritis following gastrointestinal or genitourinary infection. [1]

Plan exercise, practical support and flares

  • Refer axial disease to specialist physiotherapy for a structured individual programme covering stretching, strength, posture, breathing, spinal movement and aerobic exercise. Hydrotherapy can be considered as an adjunct. [1]
  • Consider referral for specialist therapy assessment when daily activities are difficult, including advice on physical aids and review of changing needs. Consider an individual flare plan covering contacts, self-care, pain, fatigue and possible medication changes. [1]
  • Seek specialist advice for recurrent or persistent flares, treatment with biological or targeted DMARDs, or comorbidity complicating flare management. [1]

Monitor bone health, trauma and cardiovascular risk

  • Discuss cardiovascular risk factors. Consider osteoporosis assessment every 2 years in axial disease, recognising that spinal calcification can falsely elevate spinal bone-density measurements and hip measurements may be more reliable. [1]
  • Advise people with axial spondyloarthritis about fracture susceptibility and seeking review after falls or trauma, especially with increased pain. In axial spondyloarthritis, suspected spinal fracture needs specialist confirmation and stability assessment, with spinal surgical referral for potential instability. [1]

Limitations and use

  • The complete technology-appraisal eligibility, drug selection and response thresholds are not reproduced. A drug list alone does not establish suitability.
  • The summary does not supply DMARD doses, laboratory-monitoring intervals or a treatment plan for uveitis.
  • NICE cost and access recommendations reflect the UK system; local availability and prescribing requirements may differ.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Spondyloarthritis in over 16s: diagnosis and management

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
28 February 2017
Publisher’s latest update
2 June 2017
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Do not exclude disease on a single negative finding
  • Apply the axial and peripheral referral pathways
  • Use sequential imaging without treating a negative scan as definitive
  • Match medication to axial or peripheral disease
  • Plan exercise, practical support and flares
  • Monitor bone health, trauma and cardiovascular risk
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House